‘Least Costly Alternative’ for DuoNeb Withdrawn from Nebulizer LCD

Late last month, the DME MACs advised providers the least costly
alternative for DuoNeb—which would pay for the brand
medication at the same rate as generic ipratropium and
albuterol—has been withdrawn from the nebulizer LCD.

“The provision related to the application of the least costly
alternative to the combination drug albuterol/ipratropium (e.g.,
DuoNeb) that was scheduled to be implemented on Nov. 1, 2008, is
being withdrawn. Other provisions of the policy remain in
effect.

This change will be included in an upcoming revision of the LCD
for nebulizers,” according to a MAC notice.